Education
About Us
Working with TipRanks
Follow Us
Hypha Labs (FUNI)
OTHER OTC:FUNI
FUNI Stock Chart & Stats
$0.04
>-$0.01(-17.23%)
At close: 4:00 PM EST
$0.04
>-$0.01(-17.23%)
Day’s Range― - ―
52-Week Range<$0.01 - $0.04
Previous CloseN/A
Volume205.96K
Average Volume (3M)115.83K
Market Cap
$4.21M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.94
Next Earnings
Feb 18, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding145,121,830
10 Day Avg. Volume142,592
30 Day Avg. Volume115,825
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
FUNI FAQ
What was Hypha Labs’s price range in the past 12 months?
Hypha Labs lowest stock price was <$0.01 and its highest was $0.04 in the past 12 months.
What is Hypha Labs’s market cap?
Hypha Labs’s market cap is $4.21M.
When is Hypha Labs’s upcoming earnings report date?
Hypha Labs’s upcoming earnings report date is Feb 18, 2025 which is 300 days ago.
How were Hypha Labs’s earnings last quarter?
Currently, no data Available
Is Hypha Labs overvalued?
According to Wall Street analysts Hypha Labs’s price is currently Overvalued.
Does Hypha Labs pay dividends?
Hypha Labs does not currently pay dividends.
What is Hypha Labs’s EPS estimate?
Hypha Labs’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hypha Labs have?
Hypha Labs has 145,121,830 shares outstanding.
What happened to Hypha Labs’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Hypha Labs?
Currently, no hedge funds are holding shares in FUNI
Company Description
Hypha Labs
DigiPath, Inc. engages in the provision of cannabis testing, education, training, and news coverage. It operates through the Digipath Labs and GroSciences business units. The Digipath Labs business unit focuses on testing all forms of cannabis-based products using FDA-compliant laboratory equipment and proprietary standard operating procedures. The GroSciences business unit plans to develop and license specific formulations to other producers and product makers in the industry. The company was founded by Todd Denkin on October 5, 2010 and is headquartered in Las Vegas, NV.
Technical Analysis
NovaBay Pharma
―
Aethlon Medical
―
Enveric Biosciences
―
Evaxion Biotech
―
SciSparc Ltd.
―
Ownership Overview
5.17%
Insiders
― Other Institutional Investors
94.83% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---